US20110124612A1 - Multi-phase contraceptive preparation based on a natural estrogen - Google Patents

Multi-phase contraceptive preparation based on a natural estrogen Download PDF

Info

Publication number
US20110124612A1
US20110124612A1 US13/020,913 US201113020913A US2011124612A1 US 20110124612 A1 US20110124612 A1 US 20110124612A1 US 201113020913 A US201113020913 A US 201113020913A US 2011124612 A1 US2011124612 A1 US 2011124612A1
Authority
US
United States
Prior art keywords
daily dose
dose units
ovulation
oestradiol valerate
dienogest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/020,913
Inventor
Jan Endrikat
Bernd Duesterberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110124612(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US13/020,913 priority Critical patent/US20110124612A1/en
Publication of US20110124612A1 publication Critical patent/US20110124612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

  • the invention relates to a multiphase product for contraception based on a natural oestrogen with a synthetic progestogen.
  • this multiphase product achieves a greater contraceptive reliability over the entire duration of the cycle, improves the cyclic bleeding behaviour and minimizes or eliminates side effects such as breast tenderness, headaches, depressive moods and libido changes and the like.
  • the patent literature discloses multiphase products based on natural oestrogens in combination with progestogens.
  • the patent EP 0 770 388 B1 describes a multiphase product for contraception whose first phase consists of to 4 daily dose units, and each daily dose unit contains as active ingredient exclusively natural oestrogens.
  • the second phase of the multiphase product consists of 2 groups of daily dose units with a combination of at least one natural oestrogen and at least one synthetic or natural progestogen.
  • the first group is formed by 5 to 3 daily dose units and the second group is formed by 17 to 13 daily dose units.
  • a third phase consists of 2 to 4 daily dose units, and each daily dose unit contains as active ingredient exclusively natural oestrogens.
  • the daily dose unit of natural oestrogen remains constant within the phases, but falls from phase 1 to phase 3.
  • the proportion of synthetic or natural progestogen in the second group of the second phase exceeds the proportion in the first group.
  • a final phase consists of 2 to 4 daily dose units, and each daily dose unit contains as active ingredient a pharmaceutically acceptable placebo.
  • Use example 5 indicates a combination of oestradiol valerate with dienogest.
  • 3 daily dose units of 3 mg of oestradiol valerate in the first phase 3 daily dose units of 3 mg of oestradiol valerate, in the second phase, in the first group, 4 daily dose units of 2 mg of oestradiol valerate plus 1 mg of dienogest, in the second group of this second phase 16 daily dose units of 2 mg of oestradiol valerate plus 2 mg of dienogest and in the third phase 2 daily dose units of 1 mg of oestradiol valerate are administered.
  • the last phase contains 3 daily dose units of pharmaceutically acceptable placebo.
  • progesterone serum concentration was measured radio-immunologically. A limit of 4.0 ng/ml progesterone has been stated. The average rate of irregular bleeding (breakthrough bleeding and spotting) fell by 45 to 53% from the first intake cycle to the last intake cycle.
  • TAUBERT, H.-D. and KUHL, H. (Kontrazeption mit Hormonen, editors Taubert, H.-D. et al., Georg Thieme Verlag Stuttgart/New York (1995), p. 160) show that there is no connection whatsoever between the occurrence of irregular bleeding and low serum concentrations of the oestrogen, in this case ethinyl-oestradiol, or of the particular progestogen.
  • This object is achieved according to the invention by a multiphase product for contraception, whose first phase consists of 2 daily dose units of 3 mg of the natural oestrogen oestradiol valerate.
  • a second phase consists of 2 groups of daily dose units, where a the first group contains 5 daily dose units of a combination of 2 mg of oestradiol valerate and at least twice or three times the ovulation-inhibitory dose of a synthetic progestogen.
  • the second group of the second phase consists of 17 daily dose units of a combination of 2 mg of oestradiol valerate and at least three times or four times the ovulation inhibitory does of a synthetic progestogen.
  • a third phase contains 2 daily dose units with 1 mg of oestradiol valerate and a further phase 2 daily dose units of pharmaceutically acceptable placebo.
  • progestational active ingredient use may advantageously be made of dienogest, drospirenone or a progestogen at at least twice its known ovulation-inhibitory dose.
  • the multiphase product according to the invention is particularly suitable for oral administration, but intravaginal, parenteral, including topical, rectal, intranasal, intrabuccal or sublingual administrations are also conceivable as dosage forms.
  • the multiphase product is produced with the conventional solid or liquid carriers or diluents and the excipients conventionally used in pharmaceutical technology appropriate for the desired mode of administration with a suitable dosage in a known manner.
  • Tablets film-coated tablets, sugar-coated tablets or hard gelatin capsules are preferably used for oral administration.
  • the invention is to be demonstrated by some examples of use.
  • the contraceptive reliability in particular the cyclic bleeding behaviour of the woman, and the tolerability of the administration regimen is demonstrated.
  • the contraceptive reliability was demonstrated in principle by determining the Hoogland score which uses the follicle size, the oestradiol level and progesterone values.
  • the progesterone serum concentration was measured radio-immunologically on selected days of the cycle, and the number of ovulations (Hoogland score 6) and of luteinized, non-ruptured follicles (Hoogland score 5) was determined.
  • the cycle stability was assessed on the basis of a bleeding pattern recorded for each cycle. Of particular interest in this connection was the occurrence of irregular bleeding (spotting or breakthrough bleeding). The mode of recording was standardized. The data were analysed descriptively.
  • the tolerability was tested on the basis of subjective feelings such as headaches, depressive moods, breast tenderness, gastric upsets (nausea/vomiting), oedemas and libido changes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenon and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenon, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.

Description

    TECHNICAL FIELD
  • The invention relates to a multiphase product for contraception based on a natural oestrogen with a synthetic progestogen.
  • Compared with the generic conventional ovulation-inhibiting products which have proved to be reliable and safe on wide use for a long time, this multiphase product achieves a greater contraceptive reliability over the entire duration of the cycle, improves the cyclic bleeding behaviour and minimizes or eliminates side effects such as breast tenderness, headaches, depressive moods and libido changes and the like.
    • PRIOR ART
  • The patent literature discloses multiphase products based on natural oestrogens in combination with progestogens.
  • The patent EP 0 770 388 B1 describes a multiphase product for contraception whose first phase consists of to 4 daily dose units, and each daily dose unit contains as active ingredient exclusively natural oestrogens. The second phase of the multiphase product consists of 2 groups of daily dose units with a combination of at least one natural oestrogen and at least one synthetic or natural progestogen. In this case, the first group is formed by 5 to 3 daily dose units and the second group is formed by 17 to 13 daily dose units. A third phase consists of 2 to 4 daily dose units, and each daily dose unit contains as active ingredient exclusively natural oestrogens. The daily dose unit of natural oestrogen remains constant within the phases, but falls from phase 1 to phase 3. The proportion of synthetic or natural progestogen in the second group of the second phase exceeds the proportion in the first group. A final phase consists of 2 to 4 daily dose units, and each daily dose unit contains as active ingredient a pharmaceutically acceptable placebo.
  • Use example 5 indicates a combination of oestradiol valerate with dienogest. In this case, in the first phase 3 daily dose units of 3 mg of oestradiol valerate, in the second phase, in the first group, 4 daily dose units of 2 mg of oestradiol valerate plus 1 mg of dienogest, in the second group of this second phase 16 daily dose units of 2 mg of oestradiol valerate plus 2 mg of dienogest and in the third phase 2 daily dose units of 1 mg of oestradiol valerate are administered. The last phase contains 3 daily dose units of pharmaceutically acceptable placebo.
  • For information on contraceptive reliability, the progesterone serum concentration was measured radio-immunologically. A limit of 4.0 ng/ml progesterone has been stated. The average rate of irregular bleeding (breakthrough bleeding and spotting) fell by 45 to 53% from the first intake cycle to the last intake cycle.
  • It is additionally known that the contraceptive reliability of combination products derives from the effect of both components, of the oestrogen and of the progestogen.
  • It is also known that the ovulation-inhibitory dose requires 1.0 mg a day for dienogest—Dienogest: Präklinik and Klinik eines neuen Gestagens, edited by A. T. Teichmann, Walter de Gruyter Berlin/New York (1995), p. 101) and 2.0-3.0 mg for drospirenone (Rosenbaum P, Schmidt W, Helmerhorst F M et al., Inhibition of ovulation by a novel progestogen (drospirenone) . . . , Eur contracept. Reprod. Health Care 5: 16-24 (2000)).
  • Moreover, TAUBERT, H.-D. and KUHL, H. (Kontrazeption mit Hormonen, editors Taubert, H.-D. et al., Georg Thieme Verlag Stuttgart/New York (1995), p. 160) show that there is no connection whatsoever between the occurrence of irregular bleeding and low serum concentrations of the oestrogen, in this case ethinyl-oestradiol, or of the particular progestogen.
    • FIELD OF THE INVENTION
  • It is consequently an object of the invention to indicate a composition for hormonal contraception based on a natural oestrogen which, compared with the generic conventional ovulation-inhibiting compositions based on natural oestrogens, achieves a greater contraceptive reliability over the entire duration of the cycle, improves the cyclic bleeding behaviour, and controls side effects such as breast tenderness, headaches, depressive moods and libido changes and the like. This object is achieved according to the invention by a multiphase product for contraception, whose first phase consists of 2 daily dose units of 3 mg of the natural oestrogen oestradiol valerate. A second phase consists of 2 groups of daily dose units, where a the first group contains 5 daily dose units of a combination of 2 mg of oestradiol valerate and at least twice or three times the ovulation-inhibitory dose of a synthetic progestogen. The second group of the second phase consists of 17 daily dose units of a combination of 2 mg of oestradiol valerate and at least three times or four times the ovulation inhibitory does of a synthetic progestogen. A third phase contains 2 daily dose units with 1 mg of oestradiol valerate and a further phase 2 daily dose units of pharmaceutically acceptable placebo.
  • As synthetic progestational active ingredient, use may advantageously be made of dienogest, drospirenone or a progestogen at at least twice its known ovulation-inhibitory dose.
  • The multiphase product according to the invention is particularly suitable for oral administration, but intravaginal, parenteral, including topical, rectal, intranasal, intrabuccal or sublingual administrations are also conceivable as dosage forms.
  • The multiphase product is produced with the conventional solid or liquid carriers or diluents and the excipients conventionally used in pharmaceutical technology appropriate for the desired mode of administration with a suitable dosage in a known manner.
  • Tablets, film-coated tablets, sugar-coated tablets or hard gelatin capsules are preferably used for oral administration.
    • EXEMPLARY EMBODIMENTS
  • The invention is to be demonstrated by some examples of use. In this connection, in particular the contraceptive reliability, the cyclic bleeding behaviour of the woman, and the tolerability of the administration regimen is demonstrated.
    • Contraceptive Reliability
  • The contraceptive reliability was demonstrated in principle by determining the Hoogland score which uses the follicle size, the oestradiol level and progesterone values. In the present case, the progesterone serum concentration was measured radio-immunologically on selected days of the cycle, and the number of ovulations (Hoogland score 6) and of luteinized, non-ruptured follicles (Hoogland score 5) was determined.
    • Cycle Stability
  • The cycle stability was assessed on the basis of a bleeding pattern recorded for each cycle. Of particular interest in this connection was the occurrence of irregular bleeding (spotting or breakthrough bleeding). The mode of recording was standardized. The data were analysed descriptively.
    • Tolerability
  • The tolerability was tested on the basis of subjective feelings such as headaches, depressive moods, breast tenderness, gastric upsets (nausea/vomiting), oedemas and libido changes.
    • Use Example 1
  • The following regimen was used:
  •
    days 1 to 2 3 mg of oestradiol valerate/d
    days 3 to 7 2 mg of oestradiol valerate/d + 2 mg of
    dienogest/d
    days 8 to 24 2 mg of oestradiol valerate/d + 3 mg of
    dienogest/d
    days 25 to 26 1 mg of oestradiol valerate/d
    days 27 to 28 placebo
  • The study was carried out on 93 female subjects 18 to 35 years old. The duration of intake amounted to 3 cycles in each case, with only cycles 2 and 3 being observed.
  • In the 2nd cycle (primary target variable), 3 of 93 women (3.23%) ovulated, and 2 of 92 women in the 3rd cycle.
  • It was thus possible to record reliable inhibition of ovulation in 96.77% on use of the administration regimen according to the invention.
  • At the same time, good tolerability is found on intake of the administration regimen according to the invention.
    • Use Example 2
  • days 1 to 2 3 mg of oestradiol valerate/d
    days 3 to 7 2 mg of oestradiol valerate/d + 3 mg of
    dienogest/d
    days 8 to 24 2 mg of oestradiol valerate/d + 4 mg of
    dienogest/d
    days 25 to 26 1 mg of oestradiol valerate/d
    days 27 to 28 placebo
  • The study was carried out on 93 female subjects 18 to years old. The duration of intake amounted to 3 cycles in each case, with only cycles 2 and 3 being observed.
  • In the 2nd cycle (primary target variable), 2 of 93 women (2.15%) ovulated, and 2 of 92 women in the 3rd cycle.
  • It was thus possible to record reliable inhibition of ovulation in 97.85% on use of the administration regimen according to the invention.
  • At the same time, good tolerability is found on intake of the administration regimen according to the invention.
  • It is possible with the two use examples to record an adequate inhibition of ovulation of respectively 97.85% and 96.77%. Very recent investigations with conventional ovulation inhibitors by Pierson R A et al., “Ortho Evra/Evra versus oral contraceptives: follicular development . . . ”, Fertil. Steril. 80(1), pp. 34-42 (2003) demonstrate ovulation in a certain percentage even with products which have proved to be reliable and safe on wide use for a long time. In the second treatment cycle it was possible to observe ovulations for example with a three-phase levonorgestrel-containing oral contraceptive in 14% (3 of 22), with a monophasic levonorgestrel-containing oral contraceptive (6 of 25) and with a triphasic norgestimate-containing oral contraceptive in 16% (4 of 25). These values are distinctly above those for the products according to the invention, so that a higher reliability can be expected with these compared with Pierson et al.

Claims (2)

1. Multiphase product for contraception based on a natural oestrogen with a synthetic progestogen characterized in that the first phase consists of 2 daily dose units of 3 mg of the natural oestrogen oestradiol valerate,
a second phase consists of 2 groups of daily dose units, where the first group is formed by 5 daily dose units of a combination of 2 mg of oestradiol valerate and at least twice or three times the ovulation-inhibitory dose of a synthetic progestogen,
and the second group is formed by 17 daily dose units of a combination of 2 mg of oestradiol valerate and at least three times or four times the ovulation-inhibitory dose of a synthetic progestogen,
a third phase consists of 2 daily dose units with 1 mg of oestradiol valerate,
and a further phase consists of 2 daily dose units of pharmaceutically acceptable placebo.
2. Multiphase product according to claim 1, characterized in that the synthetic progestational active ingredient is dienogest, drospirenone or a progestogen at at least twice its known ovulation-inhibitory dose.
US13/020,913 2004-04-20 2011-02-04 Multi-phase contraceptive preparation based on a natural estrogen Abandoned US20110124612A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/020,913 US20110124612A1 (en) 2004-04-20 2011-02-04 Multi-phase contraceptive preparation based on a natural estrogen

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE102004019743A DE102004019743B4 (en) 2004-04-20 2004-04-20 Multiphase preparation for contraception based on natural estrogen
DE102004019743.1 2004-04-20
PCT/EP2005/004022 WO2005102247A2 (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
US57877107A 2007-06-27 2007-06-27
US12/726,799 US20100173877A1 (en) 2004-04-20 2010-03-18 Multi-phase contraceptive preparation based on a natural estrogen
US13/020,913 US20110124612A1 (en) 2004-04-20 2011-02-04 Multi-phase contraceptive preparation based on a natural estrogen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/726,799 Continuation US20100173877A1 (en) 2004-04-20 2010-03-18 Multi-phase contraceptive preparation based on a natural estrogen

Publications (1)

Publication Number Publication Date
US20110124612A1 true US20110124612A1 (en) 2011-05-26

Family

ID=34979546

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/578,771 Active 2026-05-13 US8071577B2 (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
US12/726,799 Abandoned US20100173877A1 (en) 2004-04-20 2010-03-18 Multi-phase contraceptive preparation based on a natural estrogen
US13/020,913 Abandoned US20110124612A1 (en) 2004-04-20 2011-02-04 Multi-phase contraceptive preparation based on a natural estrogen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/578,771 Active 2026-05-13 US8071577B2 (en) 2004-04-20 2005-04-15 Multi-phase contraceptive preparation based on a natural estrogen
US12/726,799 Abandoned US20100173877A1 (en) 2004-04-20 2010-03-18 Multi-phase contraceptive preparation based on a natural estrogen

Country Status (38)

Country Link
US (3) US8071577B2 (en)
EP (1) EP1740163B2 (en)
JP (1) JP4908399B2 (en)
KR (1) KR20060134168A (en)
CN (1) CN1946383B (en)
AR (2) AR048830A1 (en)
AT (1) ATE473734T1 (en)
AU (1) AU2005235418C1 (en)
BR (1) BRPI0510005A (en)
CA (1) CA2561839C (en)
CR (1) CR8695A (en)
CY (1) CY1111292T1 (en)
DE (2) DE102004019743B4 (en)
DK (1) DK1740163T4 (en)
EA (1) EA010313B1 (en)
EC (1) ECSP067000A (en)
ES (1) ES2348038T5 (en)
GT (1) GT200500093A (en)
HK (1) HK1099701A1 (en)
HR (1) HRP20100513T4 (en)
IL (2) IL178510A (en)
ME (1) ME01183B (en)
MX (1) MXPA06012213A (en)
MY (1) MY143669A (en)
NO (1) NO344098B1 (en)
NZ (1) NZ550417A (en)
PA (1) PA8630901A1 (en)
PE (1) PE20060308A1 (en)
PL (1) PL1740163T5 (en)
PT (1) PT1740163E (en)
RS (1) RS51434B2 (en)
SI (1) SI1740163T2 (en)
SV (1) SV2006002090A (en)
TW (1) TWI351960B (en)
UA (1) UA83915C2 (en)
UY (1) UY28863A1 (en)
WO (1) WO2005102247A2 (en)
ZA (1) ZA200609594B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
ES2382459T3 (en) * 2005-10-13 2012-06-08 Bayer Pharma Aktiengesellschaft Use of estradiol valerate, in combination with dienogest for oral therapy of dysfunctional uterine bleeding, in conjunction with oral contraception
PT1787649E (en) * 2005-10-13 2009-05-08 Bayer Schering Pharma Ag Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1993531B1 (en) * 2006-03-02 2015-10-14 Warner Chilcott Company, LLC Extended cycle multiphasic oral contraceptive method
DE102006010329A1 (en) * 2006-03-06 2007-09-13 Höltge, Michael, Dipl.-Med. Hormonal contraceptive, comprises combination preparation of testosterone, gestogen, and esterogen, in the form of single, double or multi-phase preparation
EP1930010A1 (en) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido
US20090117184A1 (en) * 2007-11-05 2009-05-07 Sabine Fricke Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception
AR086395A1 (en) * 2011-05-11 2013-12-11 Kirax Corp PACKAGE FOR TREATMENT OF PATHOLOGIES

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378356A (en) * 1980-03-18 1983-03-29 Akzon N.V. Multi-phase combination-type sequential preparation for oral contraception and method of oral contraception
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US5280023A (en) * 1991-02-09 1994-01-18 Marika Ehrlich Ovulation-inhibiting preparation for hormonal contraception
US5633242A (en) * 1994-08-12 1997-05-27 Oettel; Michael Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component
US6027749A (en) * 1995-06-28 2000-02-22 Schering Ag Pharmaceutical combined preparation, kit and method for hormonal contraception
US6133251A (en) * 1995-10-28 2000-10-17 Jenapharm Gmbh & Co. Kg Combination compound for contraception based on natural estrogen
US6312772B1 (en) * 1997-10-20 2001-11-06 Hoechst Celanese Corporation Multilayer laminate formed from a substantially stretched non-molten wholly aromatic liquid crystalline polymer and non-polyester thermoplastic polymer
US6670350B1 (en) * 1999-02-18 2003-12-30 Jenapharm Gmbh & Co. Kg Method of administering dienogest in high dosages to reduce the body of the breast and pharmaceutical composition for same
US6782282B2 (en) * 2001-03-02 2004-08-24 Hartmut Ulrich Bielefeldt Superconductor system with enhanced current carrying capability
US20040266745A1 (en) * 2001-09-29 2004-12-30 Solvay Pharmaceuticals Gmbh Estrogen-gestagen combination preparations and uses thereof
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
US20050282790A1 (en) * 1996-12-20 2005-12-22 Norman Nashed Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
US20060135496A1 (en) * 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070111977A1 (en) * 2005-10-17 2007-05-17 Susan Zeun Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US20070259840A1 (en) * 2004-04-20 2007-11-08 Schering Ag Multi-Phase Contraceptive Preparation Based on a Natural Estrogen
US20080125401A1 (en) * 2006-10-20 2008-05-29 Susan Zeun Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (en) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Use of hormones for contraception
DE2431704A1 (en) 1974-07-02 1976-01-22 Asche Ag Three-stage combination oral contraceptives - contg. oestrogen with increasing doses of gestagen
DE2645307A1 (en) 1976-10-05 1978-04-06 Schering Ag NEW MEANS AND NEW METHODS FOR TREATING CLIMATE FAILURE
JPS6019734B2 (en) 1977-05-12 1985-05-17 三共株式会社 Method for producing stable prostaglandin E preparations
US4272270A (en) 1979-04-04 1981-06-09 Petrochem Consultants, Inc. Cryogenic recovery of liquid hydrocarbons from hydrogen-rich
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (en) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Three-phase product for contraception composed of ethinylestradiol and lynestrenol
DE3347125A1 (en) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4224534A1 (en) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
DE4308406C1 (en) 1993-03-12 1994-06-16 Jenapharm Gmbh Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen
DE4313926A1 (en) * 1993-04-28 1994-11-03 Jenapharm Gmbh Multiphase pharmaceutical product for hormonal contraception
DE4339934C2 (en) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Anti-ovulation agent for hormonal contraception
NL9301562A (en) 1993-09-09 1995-04-03 Saturnus Ag Substitution therapy preparation.
DE4344462C2 (en) 1993-12-22 1996-02-01 Schering Ag Composition for contraception
AU4043597A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen
CA2261687A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
ATE271386T1 (en) 1996-07-26 2004-08-15 Wyeth Corp ORAL SINGLE STAGE CONTRACEPTION METHOD AND COMBINATION PRODUCT CONTAINING PROGESTEN AND ESTROGEN
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE10045380A1 (en) 2000-09-14 2002-04-04 Schering Ag Contraception procedure and dosage form
EP1462106A1 (en) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
ATE419855T1 (en) * 2003-06-25 2009-01-15 Bayer Schering Pharma Ag THERAPY FOR HORMONE REPLACEMENT AND DEPRESSION CONTAINING DIENOGEST
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
PT1787649E (en) 2005-10-13 2009-05-08 Bayer Schering Pharma Ag Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378356A (en) * 1980-03-18 1983-03-29 Akzon N.V. Multi-phase combination-type sequential preparation for oral contraception and method of oral contraception
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US5280023A (en) * 1991-02-09 1994-01-18 Marika Ehrlich Ovulation-inhibiting preparation for hormonal contraception
US5633242A (en) * 1994-08-12 1997-05-27 Oettel; Michael Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component
US6027749A (en) * 1995-06-28 2000-02-22 Schering Ag Pharmaceutical combined preparation, kit and method for hormonal contraception
US6884793B2 (en) * 1995-10-28 2005-04-26 Jenapharm Gmbh & Co. Kg Combination preparation for contraception based on natural estrogens
US20020107229A1 (en) * 1995-10-28 2002-08-08 Michael Dittgen Combination preparation for contraception based on naural estrogens
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
US6133251A (en) * 1995-10-28 2000-10-17 Jenapharm Gmbh & Co. Kg Combination compound for contraception based on natural estrogen
US20050282790A1 (en) * 1996-12-20 2005-12-22 Norman Nashed Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
US6312772B1 (en) * 1997-10-20 2001-11-06 Hoechst Celanese Corporation Multilayer laminate formed from a substantially stretched non-molten wholly aromatic liquid crystalline polymer and non-polyester thermoplastic polymer
US6670350B1 (en) * 1999-02-18 2003-12-30 Jenapharm Gmbh & Co. Kg Method of administering dienogest in high dosages to reduce the body of the breast and pharmaceutical composition for same
US6782282B2 (en) * 2001-03-02 2004-08-24 Hartmut Ulrich Bielefeldt Superconductor system with enhanced current carrying capability
US20040266745A1 (en) * 2001-09-29 2004-12-30 Solvay Pharmaceuticals Gmbh Estrogen-gestagen combination preparations and uses thereof
US20070259840A1 (en) * 2004-04-20 2007-11-08 Schering Ag Multi-Phase Contraceptive Preparation Based on a Natural Estrogen
US20060135496A1 (en) * 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20070111977A1 (en) * 2005-10-17 2007-05-17 Susan Zeun Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US20080125401A1 (en) * 2006-10-20 2008-05-29 Susan Zeun Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido

Also Published As

Publication number Publication date
HRP20100513T4 (en) 2020-10-02
ES2348038T3 (en) 2010-11-29
ATE473734T1 (en) 2010-07-15
IL178510A0 (en) 2007-02-11
CR8695A (en) 2008-07-29
WO2005102247A2 (en) 2005-11-03
BRPI0510005A (en) 2007-09-18
ES2348038T5 (en) 2020-09-14
TW200534860A (en) 2005-11-01
UA83915C2 (en) 2008-08-26
IL178510A (en) 2015-08-31
EP1740163B2 (en) 2020-01-15
HRP20100513T1 (en) 2010-11-30
DE102004019743A1 (en) 2005-11-24
SI1740163T1 (en) 2010-11-30
RS51434B2 (en) 2020-11-30
HK1099701A1 (en) 2007-08-24
WO2005102247A3 (en) 2006-01-12
SV2006002090A (en) 2006-02-15
AR084229A2 (en) 2013-05-02
UY28863A1 (en) 2005-11-30
AU2005235418A1 (en) 2005-11-03
RS51434B (en) 2011-04-30
CA2561839A1 (en) 2005-11-03
PL1740163T5 (en) 2020-10-05
PA8630901A1 (en) 2006-05-16
DK1740163T4 (en) 2020-04-06
KR20060134168A (en) 2006-12-27
ZA200609594B (en) 2008-04-30
SI1740163T2 (en) 2020-04-30
DE502005009904D1 (en) 2010-08-26
US8071577B2 (en) 2011-12-06
MY143669A (en) 2011-06-30
US20070259840A1 (en) 2007-11-08
JP4908399B2 (en) 2012-04-04
EA200601844A1 (en) 2007-04-27
CN1946383B (en) 2010-06-09
PE20060308A1 (en) 2006-05-25
MXPA06012213A (en) 2007-01-17
TWI351960B (en) 2011-11-11
IL239861A0 (en) 2015-08-31
EP1740163B1 (en) 2010-07-14
CA2561839C (en) 2009-09-29
PL1740163T3 (en) 2010-12-31
ME01183B (en) 2013-03-20
NO20065292L (en) 2007-01-17
EA010313B1 (en) 2008-08-29
DE102004019743B4 (en) 2008-11-27
ECSP067000A (en) 2006-12-29
PT1740163E (en) 2010-09-28
US20100173877A1 (en) 2010-07-08
CY1111292T1 (en) 2015-08-05
AU2005235418C1 (en) 2015-05-21
JP2007533681A (en) 2007-11-22
AU2005235418B2 (en) 2009-08-06
NZ550417A (en) 2010-01-29
DK1740163T3 (en) 2010-10-18
EP1740163A2 (en) 2007-01-10
GT200500093A (en) 2006-04-17
NO344098B1 (en) 2019-09-02
AR048830A1 (en) 2006-05-31
CN1946383A (en) 2007-04-11

Similar Documents

Publication Publication Date Title
US20110124612A1 (en) Multi-phase contraceptive preparation based on a natural estrogen
USRE39861E1 (en) Methods of extended use oral contraception
RU2165258C2 (en) Pharmaceutical combined preparation for hormonal contraception
SK281709B6 (en) Multiphase contraceptive preparation based on natural oestrogens
US6506390B2 (en) Progestogen-anti-progestogen regimens
JP2007535519A (en) Management of broken bleeding in extended hormonal contraception
CA2241192A1 (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
SK121996A3 (en) Progesterone antagonists useful for preparing medicaments for treating dysfunctional uterine bleeding
US5980940A (en) Pharmaceutical combination preparation for hormonal contraception
US6642219B1 (en) Progestogen-antiprogestogen regimens
JP2000515889A (en) Biphasic contraceptive method and kit comprising a mixture of progestin and estrogen
US20050032756A1 (en) Multistage preparation for contraception based on natural estrogens
US4870067A (en) Oxytocins and antigestagens in combination for induction of birth
WO2000009136A1 (en) Progestogen-only contraceptive kit providing good cycle control
CZ284596A3 (en) Progesterone antagonists for preparing medicaments applied for treating dysfunctional uterine bleeding

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION